All Title Author
Keywords Abstract

PLOS ONE  2014 

Dietary Medium Chain Fatty Acid Supplementation Leads to Reduced VLDL Lipolysis and Uptake Rates in Comparison to Linoleic Acid Supplementation

DOI: 10.1371/journal.pone.0100376

Full-Text   Cite this paper   Add to My Lib


Dietary medium chain fatty acids (MCFA) and linoleic acid follow different metabolic routes, and linoleic acid activates PPAR receptors. Both these mechanisms may modify lipoprotein and fatty acid metabolism after dietary intervention. Our objective was to investigate how dietary MCFA and linoleic acid supplementation and body fat distribution affect the fasting lipoprotein subclass profile, lipoprotein kinetics, and postprandial fatty acid kinetics. In a randomized double blind cross-over trial, 12 male subjects (age 51±7 years; BMI 28.5±0.8 kg/m2), were divided into 2 groups according to waist-hip ratio. They were supplemented with 60 grams/day MCFA (mainly C8:0, C10:0) or linoleic acid for three weeks, with a wash-out period of six weeks in between. Lipoprotein subclasses were measured using HPLC. Lipoprotein and fatty acid metabolism were studied using a combination of several stable isotope tracers. Lipoprotein and tracer data were analyzed using computational modeling. Lipoprotein subclass concentrations in the VLDL and LDL range were significantly higher after MCFA than after linoleic acid intervention. In addition, LDL subclass concentrations were higher in lower body obese individuals. Differences in VLDL metabolism were found to occur in lipoprotein lipolysis and uptake, not production; MCFAs were elongated intensively, in contrast to linoleic acid. Dietary MCFA supplementation led to a less favorable lipoprotein profile than linoleic acid supplementation. These differences were not due to elevated VLDL production, but rather to lower lipolysis and uptake rates.


[1]  Walker C, Reamy BV (2009) Diets for cardiovascular disease prevention: What is the evidence? Am Fam Phys 79: 571–578.
[2]  St-Onge MP, Bosarge A (2008) Weight-loss diet that includes consumption of medium-chain triacylglycerol oil leads to a greater rate of weight and fat mass loss than does olive oil. Am J Clin Nutr 87: 621–626.
[3]  Marten B, Pfeuffer M, Schrezenmeir J (2006) Medium-chain triglycerides. Int Dairy J 16: 1374–1382. doi: 10.1016/j.idairyj.2006.06.015
[4]  Horrobin DF, Huang YS (1987) The role of linoleic acid and its metabolites in the lowering of plasma cholesterol and the prevention of cardiovascular disease. Int J Cardiol 17: 241–255. doi: 10.1016/0167-5273(87)90073-8
[5]  Bach AC, Babayan VK (1982) Medium-chain triglycerides: An update. Am J Clin Nutr 36: 950–962.
[6]  van Schalkwijk DB, de Graaf AA, van Ommen B, van Bochove K, Rensen PCN, et al. (2009) Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. J Lipid Res 50: 2398–2411. doi: 10.1194/jlr.m800354-jlr200
[7]  Shen BW, Scanu AM, Kezdy FJ (1977) Structure of human serum lipoproteins inferred from compositional analysis. Proc Natl Acad Sci U S A 74: 837–841. doi: 10.1073/pnas.74.3.837
[8]  Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94: 4312–4317. doi: 10.1073/pnas.94.9.4312
[9]  Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, et al. (1997) Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay. Mol Endocrinol 11: 779–791. doi: 10.1210/mend.11.6.0007
[10]  Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors and . Proc Natl Acad Sci USA 94: 4318–4323. doi: 10.1073/pnas.94.9.4318
[11]  Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, et al. (1998) Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation 98: 2088–2093. doi: 10.1161/01.cir.98.19.2088
[12]  Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, et al. (2004) Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 45: 174–185. doi: 10.1194/jlr.m300309-jlr200
[13]  van Bochove C, van Schalkwijk DB, Parnell LD, Lai CQ, Ordovas JM, et al. (2012) Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy. PLoS One 7: e38072.
[14]  Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, et al. (2007) Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99: 56i–67i. doi: 10.1016/j.amjcard.2007.03.024
[15]  Lear SA, Humphries KH, Kohli S, Frohlich JJ, Birmingham CL, et al. (2007) Visceral adipose tissue, a potential risk factor for carotid atherosclerosis: Results of the Multicultural Community Health Assessment Trial (M-CHAT). Stroke 38: 2422–2429.
[16]  Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J (2010) Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular riska review of the literature. Eur J Clin Nutr 64: 16–22. doi: 10.1038/ejcn.2009.68
[17]  Biolo G, Toigo G, Guarnieri G (2001) Slower activation of insulin action in upper body obesity. Metabolism 50: 19–23. doi: 10.1053/meta.2001.17726
[18]  Van Strien T, Frijters JE, Bergers G, Defares PB (1986) The Dutch Eating Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior. Int J Eat Disord 5: 295–315. doi: 10.1002/1098-108x(198602)5:2<295::aid-eat2260050209>;2-t
[19]  Kistemaker C, Bouman M, Hulshof KFAM (1998) Consumption of separate products by Dutch population groups-Dutch National Food Consumption Survey 1997–1998. TNO-report 98, 812..
[20]  Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, et al. (2005) Identification of Unique Lipoprotein Subclasses for Visceral Obesity by Component Analysis of Cholesterol Profile in High-Performance Liquid Chromatography. Arterioscler Thromb Vasc Biol 25: 578–584. doi: 10.1161/01.atv.0000155017.60171.88
[21]  McCloy U, Ryan MA, Pencharz PB, Ross RJ, Cunnane SC (2004) A comparison of the metabolism of eighteen-carbon 13C-unsaturated fatty acids in healthy women. J Lipid Res 45: 474–485. doi: 10.1194/jlr.m300304-jlr200
[22]  van Eijk HMH, Deutz NEP (2003) Plasma Protein Synthesis Measurements Using a Proteomics Strategy. J Nutr 133: 2084S–2089S.
[23]  ISO (1990) ISO 5508:1990 Animal and vegetable fats and oils - Analysis by gas chromatography of methyl esters of fatty acids.
[24]  ISO (2000) ISO 5509:2000 Animal and vegetable fats and oils - Preparation of methyl esters of fatty acids.
[25]  Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, et al. (2005) Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 25: 161–167. doi: 10.1161/01.atv.0000148866.29829.19
[26]  van Schalkwijk DB, van Ommen B, Freidig AP, van der Greef J, de Graaf AA (2011) Diagnostic Markers based on a Computational Model of Lipoprotein Metabolism. J Clin Bioinform 1: 29. doi: 10.1186/2043-9113-1-29
[27]  van Schalkwijk DB, van Bochove K, van Ommen B, Freidig AP, van Someren EP, et al. (2010) Developing computational model-based diagnostics to analyse clinical chemistry data. Brief Bioinform 11: 403–416.
[28]  van Bochove K, van Schalkwijk DB, Parnell LD, Lai CQ, Ordovas JM, et al. (2012) Clustering by Plasma Lipoprotein Profile Reveals Two Distinct Subgroups with Positive Lipid Response to Fenofibrate Therapy. PLoS One 7: e38072.
[29]  Adiels M, Packard C, Caslake MJ, Stewart P, Soro A, et al. (2005) A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 46: 58–67. doi: 10.1194/jlr.m400108-jlr200
[30]  Seidell JC, Perusse L, Despres JP, Bouchard C (2001) Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr 74: 315–321.
[31]  Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clin Chem 18: 499–502.
[32]  Asakura L, Lottenberg AMP, Neves MQTS, Nunes VS, Rocha JC, et al. (2000) Dietary medium-chain triacylglycerol prevents the postprandial rise of plasma triacylglycerols but induces hypercholesterolemia in primary hypertriglyceridemic subjects. Am J Clin Nutr 71: 701–705.
[33]  Hill JO, Peters JC, Swift LI, Yang D, Sharp T, et al. (1990) Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides. J Lipid Res 31: 407–416.
[34]  Swift LL, Hill JO, Peters JC, Greene HL (1992) Plasma lipids and lipoproteins during 6 d of maintenance feeding with long-chain, medium-chain, and mixed-chain triglycerides. Am J Clin Nutr 56: 881–886.
[35]  St-Onge MP, Jones PJH (2003) Greater rise in fat oxidation with medium-chain triglyceride consumption relative to long-chain triglyceride is associated with lower initial body weight and greater loss of subcutaneous adipose tissue. Int J Obesity 27: 1565–1571. doi: 10.1038/sj.ijo.0802467
[36]  St-Onge MP, Ross R, Parsons WD, Jones PJH (2003) Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men. Obesity Res 11: 395–402. doi: 10.1038/oby.2003.53
[37]  Sato K, Cho Y, Tachibana S, Chiba T, Schneider WJ, et al. (2005) Impairment of VLDL secretion by medium-chain fatty acids in chicken primary hepatocytes is affected by the chain length. J Nutr 135: 1636–1641.
[38]  Tachibana S, Sato K, Cho Y, Chiba T, Schneider WJ, et al. (2005) Octanoate reduces very low-density lipoprotein secretion by decreasing the synthesis of apolipoprotein B in primary cultures of chicken hepatocytes. BBA-mol cell biol l 1737: 36–43. doi: 10.1016/j.bbalip.2005.09.001
[39]  Turkenkopf IJ, Maggio CA, Greenwood MRC (1982) Effect of high fat weanling diets containing either medium-chain triglycerides or long-chain triglycerides on the development of obesity in the Zucker rat. J Nutr 112: 1254–1263.
[40]  Thomas TR, Horner KE, Langdon MM, Zhang JQ, Krul ES, et al. (2001) Effect of exercise and medium-chain fatty acids on postprandial lipemia. J Appl Physiol 90: 1239–1246.


comments powered by Disqus